Xytis Pharmaceuticals Inc.
http://www.xytis.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xytis Pharmaceuticals Inc.
Treating Traumatic Brain Injury
Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?
Recent Financings of Private Companies (02/2006)
Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
Start-Up Previews (4/05)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Building a Better Drug for Schizophrenia, features profiles of Galenea Corp., Potomac Pharma Inc., Vanda Pharmaceuticals Inc. and Xytis Pharmaceuticals Ltd. Plus these Start-Ups Across Health Care: Aqueduct Medical Inc., CryoFluor Therapeutics LLC, 3DM Inc. and Xigen SA.
Xytis Pharmaceuticals Ltd.
Xytis Pharmaceuticals Ltd., focused on in-licensing and developing late-stage CNS drug candidates, is taking a unique approach to treating schizophrenia by developing a drug that targets the NMDA receptor complex.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice